108 related articles for article (PubMed ID: 26976325)
21. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.
Seeman P; Ko F; Willeit M; McCormick P; Ginovart N
Synapse; 2005 Nov; 58(2):122-8. PubMed ID: 16088951
[TBL] [Abstract][Full Text] [Related]
22. Respective roles of dopamine D2 and D3 receptors in food-seeking behaviour in rats.
Duarte C; Biala G; Le Bihan C; Hamon M; Thiébot MH
Psychopharmacology (Berl); 2003 Feb; 166(1):19-32. PubMed ID: 12525958
[TBL] [Abstract][Full Text] [Related]
23. Disease-modifying effect of atipamezole in a model of post-traumatic epilepsy.
Nissinen J; Andrade P; Natunen T; Hiltunen M; Malm T; Kanninen K; Soares JI; Shatillo O; Sallinen J; Ndode-Ekane XE; Pitkänen A
Epilepsy Res; 2017 Oct; 136():18-34. PubMed ID: 28753497
[TBL] [Abstract][Full Text] [Related]
24. Dopamine D2-like receptor agonists induce penile erection in male rats: differential role of D2, D3 and D4 receptors in the paraventricular nucleus of the hypothalamus.
Sanna F; Succu S; Hübner H; Gmeiner P; Argiolas A; Melis MR
Behav Brain Res; 2011 Nov; 225(1):169-76. PubMed ID: 21784104
[TBL] [Abstract][Full Text] [Related]
25. Anterior ventral tegmental area dopaminergic neurons are not involved in the motivational effects of bromocriptine, pramipexole and cocaine in drug-free rats.
Ouachikh O; Dieb W; Durif F; Hafidi A
Behav Brain Res; 2014 Apr; 262():1-7. PubMed ID: 24361908
[TBL] [Abstract][Full Text] [Related]
26. The alpha2-adrenoceptor antagonist atipamezole reduces the development and expression of d-amphetamine-induced behavioural sensitization.
Juhila J; Haapalinna A; Sirviö J; Sallinen J; Honkanen A; Korpi ER; Scheinin M
Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar; 367(3):274-80. PubMed ID: 12644900
[TBL] [Abstract][Full Text] [Related]
27. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.
Ling ZD; Robie HC; Tong CW; Carvey PM
J Pharmacol Exp Ther; 1999 Apr; 289(1):202-10. PubMed ID: 10087005
[TBL] [Abstract][Full Text] [Related]
28. Distinct effects of pramipexole on the proliferation of adult mouse sub-ventricular zone-derived cells and the appearance of a neuronal phenotype.
Merlo S; Canonico PL; Sortino MA
Neuropharmacology; 2011 May; 60(6):892-900. PubMed ID: 21272591
[TBL] [Abstract][Full Text] [Related]
29. Effects of pramipexole on the processing of rewarding and aversive taste stimuli.
McCabe C; Harwood J; Brouwer S; Harmer CJ; Cowen PJ
Psychopharmacology (Berl); 2013 Jul; 228(2):283-90. PubMed ID: 23483198
[TBL] [Abstract][Full Text] [Related]
30. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells.
Presgraves SP; Borwege S; Millan MJ; Joyce JN
Exp Neurol; 2004 Nov; 190(1):157-70. PubMed ID: 15473989
[TBL] [Abstract][Full Text] [Related]
31. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.
Collins GT; Witkin JM; Newman AH; Svensson KA; Grundt P; Cao J; Woods JH
J Pharmacol Exp Ther; 2005 Jul; 314(1):310-9. PubMed ID: 15833897
[TBL] [Abstract][Full Text] [Related]
32. A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist.
Black KJ; Hershey T; Koller JM; Videen TO; Mintun MA; Price JL; Perlmutter JS
Proc Natl Acad Sci U S A; 2002 Dec; 99(26):17113-8. PubMed ID: 12482941
[TBL] [Abstract][Full Text] [Related]
33. Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.
Ostock CY; Hallmark J; Palumbo N; Bhide N; Conti M; George JA; Bishop C
Neuropharmacology; 2015 Aug; 95():215-25. PubMed ID: 25817388
[TBL] [Abstract][Full Text] [Related]
34. Differential behavioral reinforcement effects of dopamine receptor agonists in the rat with bilateral lesion of the posterior ventral tegmental area.
Ouachikh O; Dieb W; Durif F; Hafidi A
Behav Brain Res; 2013 Sep; 252():24-31. PubMed ID: 23727149
[TBL] [Abstract][Full Text] [Related]
35. Atipamezole, an alpha 2 antagonist, augments opiate-induced muscle rigidity in the rat.
Weinger MB; Bednarczyk JM
Pharmacol Biochem Behav; 1994 Nov; 49(3):523-9. PubMed ID: 7862703
[TBL] [Abstract][Full Text] [Related]
36. Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: release from adrenergic terminals and modulation by alpha2-autoreceptors.
Gobert A; Billiras R; Cistarelli L; Millan MJ
J Neurosci Methods; 2004 Dec; 140(1-2):141-52. PubMed ID: 15589344
[TBL] [Abstract][Full Text] [Related]
37. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole.
Willner P; Lappas S; Cheeta S; Muscat R
Psychopharmacology (Berl); 1994 Aug; 115(4):454-62. PubMed ID: 7871089
[TBL] [Abstract][Full Text] [Related]
38. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.
Seeman P
Synapse; 2015 Apr; 69(4):183-9. PubMed ID: 25645960
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic evaluation of pramipexole.
Antonini A; Calandrella D
Expert Opin Drug Metab Toxicol; 2011 Oct; 7(10):1307-14. PubMed ID: 21892895
[TBL] [Abstract][Full Text] [Related]
40. Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain.
Chernoloz O; El Mansari M; Blier P
Neuropsychopharmacology; 2009 Feb; 34(3):651-61. PubMed ID: 18688211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
